Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Molecular Diagnostic Techniques
  • Molecular Targeted Therapy
  • Neoplasms

abstract

  • A hypothesis test using the 75% upper confidence bound to define the lower limit of acceptable clinical activity demonstrates that the 1-year survival probability on Taxol/estramustine/carboplatin is greater than that of the historical population, and hence should be taken into a definitive trial. The design provides investigators increased confidence in making this decision.

publication date

  • January 2003

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0090-4295(02)02097-6

PubMed ID

  • 12559285

Additional Document Info

start page

  • 142

end page

  • 4

volume

  • 61

number

  • 1